Navigation Links
Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
Date:10/11/2007

tives, we will have complementary roles and provide synergistic selling efforts to launch Zingo successfully in U.S. hospitals. Anesiva will also leverage Sagent's established infrastructure for warehousing and distribution services."

"We are excited about the opportunity to collaborate with an organization of Anesiva's quality in introducing Zingo to hospital markets and will fully align our extensive hospital-focused sales and distribution resources to support Zingo," stated Jeffrey Yordon, chairman, founder and chief executive officer of Sagent Pharmaceuticals. "The Anesiva co-promote marks an important advance in Sagent's rapid evolution and Zingo fits nicely with Sagent's mission of delivering customer-focused products to patients."

About Zingo

Zingo is a ready-to-use, single-use, needle-free system that delivers 0.5 mg sterile lidocaine powder into the skin and provides topical, local analgesia in one to three minutes after administration. This rapid onset, which may be especially useful in pediatric populations and busy emergency room settings, means the product can be incorporated into a medical procedure allowing uninterrupted care, an important advantage over current options. Venous access procedures, like IV insertions and blood draws, are among the most common interventions performed at a hospital, with more than 18 million pediatric venous access procedures and 400 million total procedures per year in U.S hospitals. In addition to the hospital setting, Zingo may be used in physicians' offices and clinical laboratories. In clinical trials, Zingo was well tolerated. Common side effects were redness, red dots and swelling of the skin at the site of administration.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has one FDA-approved product, Zi
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. JT Packard exec resigns after settling copyright disputes
2. Cray signs $250M deal to develop supercomputer
3. Donley resigns as WiCell director
4. WARF signs licensing pact with BD Biosciences
5. TeraMedica signs agreement with ThedaCare
6. CATI signs agreement for food processing technology
7. Doyle signs bill that impacts electronic medical records
8. Doyle signs "self-dealing" bill
9. Electronic signs for municipalities: Las Vegas or lost revenues?
10. NorthStar signs exclusive agreement with Illinois foundation
11. Renaissance Learning CEO resigns to start company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
(Date:1/14/2014)... 2014 Date: Friday, April 11, 2014 , ... Club, 1360 Almshouse Road, Warrington, Pa. , Details: ... dedicated to finding a cure for hepatitis B and improving ... its annual Crystal Ball on Friday, April 11 at Warrington ...
(Date:1/14/2014)... provider of strategic communications services to corporations and organizations preparing for ... United States and Europe , today ... to the firm,s Washington, D.C. office. ... years of service as Associate Commissioner for the Office of External ...
(Date:1/14/2014)... , Jan. 14, 2014 The largest ... research medicinal plants and therapeutic derivatives thereof has ... professionals, and researchers about the challenges of adulterated ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society for ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... Inc. ("OriGene") today announced it has raised an ... With this financing, OriGene completed the acquisition of ... a manufacturer and provider of monoclonal antibodies (mAb) ... completes the establishment of its technology center to ...
... NKTR ) will announce its financial results ... on Wednesday, February 25, 2009, after the close,of U.S.-based ... will host a conference call to review the results ... (PT). , The press release ...
... VALLEY COTTAGE, N.Y., Feb. 11 XTL,Biopharmaceuticals Ltd. (Nasdaq: ... Mr.,David Grossman and Mr. Boaz Shweiger have been appointed ... Mr. Grossman will also be assuming,the role of Co-Chief ... of its strategic alternatives. , ...
Cached Biology Technology:OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China 2Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets 2XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors 2XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors 3
(Date:4/17/2014)... IPCC meeting painted a stark warning on the possible ... a greenhouse effect 32 times that of carbon dioxide. ... humic substances act as fully regenerable electron acceptors which ... in wetlands instead of being released to the atmosphere. ... disrupted it may enter into a vicious cycle to ...
(Date:4/17/2014)... Branch at Galveston are the first to recommend ... cancer should begin colorectal cancer screening earlier than ... a high incidence of secondary colorectal cancers among ... recommendations that the younger women in this group ... their initial cervical cancer diagnosis instead of waiting ...
(Date:4/17/2014)... a special feature of The Proceedings ... ) published April 29, raises a number of startling ... most of us take for granted. At the end ... around the globe shifted from hunting animals and gathering ... It seems so straightforward and yet the more scientists ...
Breaking Biology News(10 mins):Methane climate change risk suggested by proof of redox cycling of humic substances 2Radiation therapy for cervical cancer increases risk for colorectal cancer 2Genetic study tackles mystery of slow plant domestications 2Genetic study tackles mystery of slow plant domestications 3Genetic study tackles mystery of slow plant domestications 4
... Researchers at Albany Medical College are releasing results of a ... search for new drug targets aimed at preventing or reversing ... stroke. In the March 5 issue of the ... and his colleagues at the college,s Center for Cardiovascular Science ...
... , This release is available in German . ... beewolves, house beneficial bacteria on their cocoons that guarantee ... Institute for Chemical Ecology in Jena teamed up with ... Leibniz Institute for Natural Product Research Hans-Knoell-Institute - ...
... African-Americans age 65 and younger are more than twice ... any region, and people who have a stroke are more ... researchers at the University of Alabama at Birmingham (UAB) School ... for Geographic and Racial Differences in Stroke (REGARDS) study, one ...
Cached Biology News:Preventing or reversing inflammation after heart attack, stroke may require 2-pronged approach 2Beewolves protect their offspring with antibiotics 2Beewolves protect their offspring with antibiotics 3UAB study shows African-Americans have highest stroke rate, southerners more likely to die 2
For the quantitative determination of canine Interferon gamma,(IFN-γ) concentrations in cell culture supernates, serum and,plasma....
Request Info...
Homo sapiens olfactomedin 1, transcript variant 3...
Component of GELase™ Agarose Gel-Digesting Preparation. 1 ml of 50X Buffer is sufficient for replacing the buffer in at least 5 g of gel....
Biology Products: